Fenebrutinib is orally available inhibitor of Brutons tyrosine kinase (BTK) with antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, leading to the inhibition of the growth of malignant B-cells that overexpress BTK.
Molecular Weight:
701.27
CAS Number:
[2128304-54-9]
Formula:
C37H45ClN8O4
Target:
Others
TQ0242L
* VAT and and shipping costs not included. Errors and price changes excepted
